Question 1

What are the common side effects of Ozempic and Wegovy?

Accepted Answer

These were counted in randomised trials rather than estimated, which is unusual on this site. A 2024 JAMA review of obesity medicines gives the range for the family semaglutide belongs to: adverse effects of these drugs include nausea (28%-44%), diarrhoea (21%-30%), and constipation (11%-24%). Those bands cover liraglutide, semaglutide and tirzepatide together rather than semaglutide alone. Inside a single trial, the count of anyone reporting any digestive symptom runs higher. Over 104 weeks in 304 adults, gastrointestinal adverse events, mostly mild-to-moderate, were reported more often with semaglutide than with placebo, at 82.2% against 53.9%. The placebo column is what turns a reported symptom into an effect, and more than half of that group reported one as well. So the figure worth carrying is the gap of roughly twenty-eight percentage points, rather than the headline number on its own.

Question 2

What are the serious side effects of semaglutide?

Accepted Answer

Serious is a defined reporting category in a trial, and for semaglutide it has been pooled. A 2022 review included 4 randomized controlled trials having a total of 3,613 individuals with obesity without diabetes. It found that the risk for serious adverse events was 1.6 times more likely for semaglutide than for placebo. Where those events landed is the useful half of the finding. The review records that serious events were mostly of gastrointestinal and hepatobiliary disorders such as acute pancreatitis and cholelithiasis. Hepatobiliary means the liver and the bile ducts, and cholelithiasis means gallstones. A risk ratio of 1.6 is not a count of people, and it gets read as one all the time. It says the event came up about half as often again in one pooled group as in the other. The review does not turn that into a number out of a hundred.

Question 3

Is semaglutide safe?

Accepted Answer

We cannot answer that, and the published record does not answer it either. What exists is a tally of what the registration trials counted, and a list of the questions they left open. A 2021 review devoted to the safety of semaglutide concludes that semaglutide induces mostly mild-to-moderate and transient gastrointestinal disturbances. The same review states that no unexpected safety issues have arisen to date, which is a remark about surprises rather than a finding that harm is absent. Those two sentences are the most that the strongest evidence base on this site will support. Everything past them sits in the sections below as either a documented increase or an open question, and the difference between those two is what a reader can actually use.

Question 4

What does semaglutide do to the gallbladder?

Accepted Answer

This is the one organ where a review of the whole safety record names a documented increase rather than an open question. The 2021 safety review concludes that semaglutide increases the risk of biliary disease (cholelithiasis). Biliary disease means disease of the gallbladder and the bile ducts. The pooled trial data points the same way from the serious end, where gallstones and pancreatitis were the events that turned up most. Gallbladder events also appear by name among the topics that review set out to examine, alongside the cardiovascular aspects and the injection reactions. What no paper in these sources supplies is a rate. No published figure says how many people out of a hundred developed gallstones over a defined stretch of weekly injection, so the direction is established and the size is not. A direction without a size says what to watch for rather than how likely it is.

Question 5

Does semaglutide cause pancreatitis or thyroid cancer?

Accepted Answer

Both have been examined, and neither has been settled. The 2021 safety review works through pancreatic safety (pancreatitis and pancreatic cancer), thyroid cancer and much else, and concludes that definitive conclusions for pancreatic and thyroid cancer cannot be drawn at this point due to low incidence of these conditions. Read that carefully, because it is easy to read in whichever direction a reader arrived with. Rare events need very large populations before a trial can see a difference at all. So the absence of a conclusion reflects the size of the evidence rather than a finding that the risk is zero. Routine-care records have since been pointed at the same question. A 2025 review of real-world use reports no clear increase in risks of severe events like pancreatitis or pancreatic cancer, thyroid disorders, or depression and self-harm, drawn from observational data rather than randomised comparisons.

Question 6

Does semaglutide cause low blood sugar?

Accepted Answer

Hypoglycaemia is the first thing anyone asks about a medicine that lowers blood sugar. Hypoglycaemia means blood sugar falling too low, and the published position on this family is specific. A 2021 review of the class states that they carry no intrinsic risk of hypoglycemic episodes, which is why GLP-1RAs are recommended as the preferred first injectable glucose-lowering therapy for type 2 diabetes. The word intrinsic is carrying that sentence. The same review notes that GLP-1 RAs can be combined with (basal) insulin in either free- or fixed-dose preparations, and insulin is a compound where the risk is direct rather than intrinsic. So the hazard described in the literature belongs to the combination rather than to semaglutide alone. No published figure says how often low blood sugar occurs on semaglutide by itself.

Question 7

What happens to the eyes and the kidneys?

Accepted Answer

Both are on the list of topics that review examined, and both come back with a caution rather than a count. It warns that patients at risk for deterioration of existing DRP should be carefully monitored if treated with semaglutide, particularly if also treated with insulin. DRP is diabetic retinopathy, damage to blood vessels at the back of the eye. That is a caution about an existing condition getting worse in people who already have it, not a report of new eye disease turning up. A 2025 review of routine care says further evidence is needed to understand possible real-world associations of GLP-1RAs with eye disease and other rare outcomes. The kidney is thinner again. Acute kidney injury is named among the topics the 2021 review examined, with no rate attached to it. One trial is registered to look at renal hemodynamics and function in patients with type 2 diabetes, and it carries an unknown status with nothing among the research behind this page.

Question 8

How long do semaglutide side effects last, and when are they worst?

Accepted Answer

The published record describes a shape and declines to put a week number on either end of it. The 2021 safety review calls the digestive disturbances transient, and a 2025 review of routine care reports that these side effects are often manageable and decrease over time. Neither source says when the nausea starts, when it peaks or when it stops. No published trial covered on this page follows a single symptom from onset to resolution, so a word like transient describes a pattern rather than measuring a duration. What can be dated is the giving up. In the 2017 diabetes trial, across 30 weeks of once-weekly injection, the main reason for discontinuation was gastrointestinal adverse events such as nausea. That records when people stopped rather than when the symptom ended, and those are different questions.

Question 9

What are the long-term side effects of Ozempic and Wegovy?

Accepted Answer

Two years is the edge of the published record, and that is a shorter edge than the public conversation implies. A 2024 meta-analysis calls itself an updated systematic review and meta-analysis including the 2-year STEP 5 trial, and that trial set its co-primary endpoints at week 104. A larger and longer cardiovascular trial exists so far as a design rather than as a safety result. Its published paper describes the design of the SOUL trial and the baseline clinical data of its participants, of whom 9650 were enrolled between June 17, 2019 and March 24, 2021. A protocol paper reports what will be measured rather than what was found. A 2025 review of routine use names the same gap, calling for investigations of clinical and cost-effectiveness for hard clinical outcomes in real-world settings. Two years of counted events and an indefinite run are different questions.

Question 10

Are any of the side effects irreversible?

Accepted Answer

No trial among the research behind this page reports a reversal rate or a time course, so the answer begins with the measurement nobody took. What has been quantified is the change in body composition. A 2024 narrative review in Diabetes Care reports that these agents also cause rapid and significant loss of lean mass, at around 10% or 6 kg, comparable to a decade or more of aging. The same review explains why that belongs on a safety page, noting that maintaining muscle mass and function as humans age is crucial to avoiding sarcopenia and frailty, which are strongly linked to morbidity and mortality. Whether any of it comes back is a question no study we could find has put to a trial. That review proposes that retaining lean mass during incretin therapy could blunt body weight (and fat) regain on cessation of weight loss pharmacotherapy, which is an argument for running the study rather than a result from one.

Question 11

What are the side effects of the semaglutide pill?

Accepted Answer

The tablet carries its own trials and a much thinner adverse-event record than the injection. A 2021 safety review calls semaglutide the only GLP-1RA currently available as both subcutaneous and oral formulation, so the same molecule reaches the body two ways. What differs between the routes is not the molecule but how much of it gets into the blood. A 2024 review of the published human data reports that food and various dosing conditions including water volume and dosing schedules can affect the oral semaglutide exposure. None of that applies to a weekly shot. No trial among the research behind this page has compared the two routes head to head for side effects. The 2025 trial of the tablet assigned 205 participants to oral semaglutide and 102 to placebo, measuring against placebo rather than against an injection. So the two records sit beside one another rather than against one another.

Question 12

What interacts with semaglutide?

Accepted Answer

Less has been tested than the question implies. A 2024 systematic review of the published human exposure data reports that there are limited drug-drug interactions and no dosing adjustments in patients with upper gastrointestinal disease, renal impairment or hepatic impairment. Hepatic impairment means the liver is not working fully. One combination is documented rather than merely possible. A 2021 review of the class records that GLP-1 RAs can be combined with (basal) insulin, and the 2021 safety review counts injection-site and allergic reactions among the adverse events it worked through. Everything outside that short list is untested rather than cleared, and the distinction is the whole value of the sentence. A review finding few interactions among the studies that were run is making a claim about those studies, not about the combinations people put together at home.

Question 13

Who was excluded from the semaglutide trials?

Accepted Answer

Entry criteria did most of the excluding, and they were narrow in opposite directions. The 2021 obesity trial enrolled 1961 adults with a body-mass index of 30 or greater, or 27 or greater in persons with at least one weight-related coexisting condition, who did not have diabetes. The 2021 diabetes trial required the reverse, enrolling adults who had been diagnosed with type 2 diabetes at least 180 days before screening. So nobody at a healthy weight has been given semaglutide in these trials and watched for adverse events. The cardiovascular trial narrowed the gate again, to individuals aged over 50 years with type 2 diabetes and evidence of established arterial disease or kidney disease. Who took part shapes what the counts describe. In the two-year trial, most participants were female (236 (77.6%)) and white (283 (93.1%)), with a mean age of 47.3 years.

Question 14

What is safer, peptides or Ozempic?

Accepted Answer

The question sounds like chemistry and the answer is mostly paperwork. Potential safety concerns about semaglutide have been addressed in the extensive phase 3 registration trials, which is what produced every counted rate on this page. Most research compounds covered on this site have no equivalent tally at all. That is a difference in what has been measured rather than a ranking of risk. A compound with a long published list of side effects can be carrying fewer of them than one with an empty list, because counting is what fills the list. The comparison most readers actually mean is narrower again. A 2025 review covers adverse effects of the currently approved GLP-1RA-based weight-loss therapies, that is, liraglutide, semaglutide and tirzepatide, and the word approved is doing the work there rather than the chemical names.

Question 15

Is compounded semaglutide safe?

Accepted Answer

None of the figures above describes a compounded or research-grade vial. Every rate on this page was counted on material made to a specification filed with a regulator. An unlabelled vial has no filed specification and no adverse-event tally of its own, so none of those numbers transfer to it. What the public record holds for that supply is enforcement instead. Ten Class II recalls of semaglutide are listed: five cite Lack of Assurance of Sterility, two cite Lack of Processing Controls, one a Subpotent Drug, and one covers bulk powder pulled for failing to complete process validation and bacterial endotoxin method validation before distribution. Four of the ten cover vials blended with cyanocobalamin, a form of vitamin B12. A sterility recall is not a side-effect report. It records that a regulator could not be satisfied the contents were sterile, which is a question about contamination rather than about the compound.

Semaglutide side effects and safety data